Premium
Effect of carbazochrome sodium sulfonate on refractory chronic prostatitis
Author(s) -
Ohoka Hitoshi,
Yamada Tetsuo,
Noto Hiromitsu,
Umeyama Tomokazu,
Kadekawa Katsumi,
Ashitomi Katsuhiro,
Nishijima Saori,
Sugaya Kimio
Publication year - 2014
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/iju.12533
Subject(s) - medicine , prostatitis , microhematuria , refractory (planetary science) , adverse effect , urinalysis , nausea , gastroenterology , urination , urine , urology , urinary system , proteinuria , prostate , kidney , astrobiology , physics , cancer
Objectives To study the effect of carbazochrome sodium sulfonate, an agent that reduces capillary permeability, on refractory chronic prostatitis. Methods Patients with prostatitis refractory to at least 8 weeks of routine therapy and with urinalysis positive for microhematuria were considered for the present study. In addition to their prior therapy, the patients received carbazochrome at a dose of 30 mg three times a day. The severity of pain (score 0–10), daytime and night‐time frequency, international prostate symptom score, global self‐assessment, urine occult blood positivity, and adverse events were assessed after 4 and 8 weeks of treatment, and compared with baseline findings. Results A total of 50 patients (mean age 68.6 ± 8.5 years) were evaluable. The pain score decreased significantly from 3.2 ± 2.1 at baseline to 1.7 ± 1.4 after 4 weeks of treatment and to 1.1 ± 1.8 after 8 weeks. Daytime and night‐time frequency, storage symptoms, post‐micturition symptoms, and urine occult blood positivity also significantly improved. More than 36% of the patients gave a global self‐assessment rating of “improved” or “better” after both 4 and 8 weeks of treatment. Mild adverse events occurred in three patients; one had nausea and two developed drug rash. Conclusions Carbazochrome seems to effectively improve pain as well as storage and post‐micturition symptoms in patients with refractory chronic prostatitis.